Voriconazole penetrated well into the pulmonary epithelial lining fluid (ELF) in lung transplant patients receiving oral prophylaxis. The ELF concentrations exceeded those of the plasma, with an average ELF-toplasma ratio of 11 (؎8). A strong association between plasma and ELF concentrations (r 2 ؍ 0.95) was noted.Adequate drug penetration to the infection site is crucial for antimicrobial therapeutic optimization. The lungs are the most common site of primary infection in cases of invasive aspergillosis (9,14). Voriconazole has become a preferred agent for the treatment of invasive aspergillosis (3). Despite its widespread use in the management of pulmonary aspergillosis, the intrapulmonary penetration of voriconazole has not been reported in humans. Voriconazole is used routinely as antifungal prophylaxis in some lung transplant centers; this offers an opportunity to study the intrapulmonary penetration of the drug, since lung transplant recipients routinely undergo surveillance bronchoscopy (5, 7).This was a prospective observational pilot study. The subjects were lung transplant patients, Ն18 years of age, who had received at least six oral doses of voriconazole prior to a scheduled bronchoscopy. The Institutional Review Board approved the study, and all patients provided written informed consent prior to participation.Voriconazole treatment (6 mg/kg of body weight intravenously every 12 h for 2 doses followed by 200 mg orally twice daily) was initiated immediately after transplant and continued for approximately 4 months as standard clinical care. Bronchoalveolar lavage (BAL) was performed at 2, 4, and 8 weeks posttransplant in all patients during the voriconazole prophylaxis period. A blood sample and an aliquot of pooled BAL supernatant were acquired for study purposes during one of these procedures.Total (free and protein-bound) voriconazole concentrations were measured in the plasma and BAL supernatant by a modified high-performance liquid chromatography-electrospray ionization mass spectrometry technique (13, 18). Authentic voriconazole (UK-109,496) and an internal standard (UK-103,446) were provided by Pfizer Global Research and Development (Sandwich, United Kingdom). The standard curves were linear (r 2 ϭ 0.99) over a concentration range of 0.05 to 6.0 g/ml for the plasma and 0.001 to 0.5 g/ml for the BAL. Interday coefficients of variation were Ͻ12.6%. The concentrations of urea in the serum and BAL supernatant were measured, separately, by a colorimetric method (serum, Vitros 950 [Ortho Clinical Diagnostics, Rochester, NY]; BAL, Urea Nitrogen Reagent [Teco Diagnostics, Anaheim, CA], respectively). The volume of epithelial lining fluid (ELF) recovered in the BAL aspirate and the concentration of voriconazole in the ELF were calculated based on the urea dilution method as previously reported (1, 2, 12). A two-tailed Spearman's rank correlation test was applied to test for a relationship between plasma and ELF concentrations.Twelve patients were enrolled in the study, with BAL and blood samples succ...